CY1115071T1 - Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων - Google Patents

Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων

Info

Publication number
CY1115071T1
CY1115071T1 CY20141100152T CY141100152T CY1115071T1 CY 1115071 T1 CY1115071 T1 CY 1115071T1 CY 20141100152 T CY20141100152 T CY 20141100152T CY 141100152 T CY141100152 T CY 141100152T CY 1115071 T1 CY1115071 T1 CY 1115071T1
Authority
CY
Cyprus
Prior art keywords
combination
ovarian cancer
therapeutic treatment
contains paclitaxel
paclitaxel
Prior art date
Application number
CY20141100152T
Other languages
English (en)
Inventor
Martine Clozel
Urs Regenass
Original Assignee
Actelion Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40670930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115071(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd. filed Critical Actelion Pharmaceuticals Ltd.
Publication of CY1115071T1 publication Critical patent/CY1115071T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα συνδυασμό ενός ανταγωνιστή του υποδοχέα της ενδοθηλίνης με τον τύπο (Ι) με την πακλιταξέλη για θεραπευτική χρήση, ταυτόχρονα, ξεχωριστά ή μέσα σε μία χρονική περίοδο, για τη θεραπευτική αντιμετώπιση του καρκίνου των ωοθηκών.
CY20141100152T 2008-02-20 2014-02-26 Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων CY1115071T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2008050607 2008-02-20
EP09712334.3A EP2254570B1 (en) 2008-02-20 2009-02-19 Combination comprising paclitaxel for treating ovarian cancer

Publications (1)

Publication Number Publication Date
CY1115071T1 true CY1115071T1 (el) 2016-12-14

Family

ID=40670930

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100152T CY1115071T1 (el) 2008-02-20 2014-02-26 Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων

Country Status (19)

Country Link
US (2) US8541433B2 (el)
EP (1) EP2254570B1 (el)
JP (1) JP5514123B2 (el)
KR (1) KR20100132489A (el)
CN (1) CN101939001B (el)
AR (1) AR070456A1 (el)
AU (1) AU2009215329B2 (el)
CA (1) CA2714608A1 (el)
CY (1) CY1115071T1 (el)
DK (1) DK2254570T3 (el)
ES (1) ES2446303T3 (el)
HR (1) HRP20140215T1 (el)
MX (1) MX2010008994A (el)
PL (1) PL2254570T3 (el)
PT (1) PT2254570E (el)
RU (1) RU2494736C2 (el)
SI (1) SI2254570T1 (el)
TW (1) TWI441639B (el)
WO (1) WO2009104149A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
RU2494736C2 (ru) * 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
NZ591601A (en) 2008-08-13 2012-12-21 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan and a prostacyclin receptor agonist
EP2464218B1 (en) 2009-08-10 2015-05-27 Board of Regents, The University of Texas System Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent
US20130310407A1 (en) * 2011-02-04 2013-11-21 Actelion Pharmaceuticals Ltd. Combinations comprising macitentan for the treatment of glioblastoma multiforme
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法
CN106659765B (zh) 2014-04-04 2021-08-13 德玛医药 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
IL155805A0 (en) * 2000-12-18 2003-12-23 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
US20040138121A1 (en) * 2002-10-24 2004-07-15 Anil Gulati Method and composition for preventing and treating solid tumors
US20040121971A1 (en) 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
MY151003A (en) 2005-09-12 2014-03-31 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
RU2494736C2 (ru) * 2008-02-20 2013-10-10 Актелион Фармасьютиклз Лтд Комбинация, включающая паклитаксел, для лечения рака яичников
KR20100005486A (ko) * 2008-07-07 2010-01-15 페어차일드코리아반도체 주식회사 스위치 제어 장치 및 이를 포함하는 컨버터

Also Published As

Publication number Publication date
CA2714608A1 (en) 2009-08-27
PL2254570T3 (pl) 2014-05-30
US8541433B2 (en) 2013-09-24
AR070456A1 (es) 2010-04-07
EP2254570B1 (en) 2013-12-18
KR20100132489A (ko) 2010-12-17
TWI441639B (zh) 2014-06-21
SI2254570T1 (sl) 2014-03-31
AU2009215329A1 (en) 2009-08-27
TW200940062A (en) 2009-10-01
US20100311774A1 (en) 2010-12-09
JP2011512399A (ja) 2011-04-21
HRP20140215T1 (hr) 2014-04-11
RU2010138650A (ru) 2012-03-27
PT2254570E (pt) 2014-02-17
ES2446303T3 (es) 2014-03-07
AU2009215329B2 (en) 2014-08-21
CN101939001A (zh) 2011-01-05
DK2254570T3 (da) 2014-02-03
CN101939001B (zh) 2012-06-20
RU2494736C2 (ru) 2013-10-10
US20130317048A1 (en) 2013-11-28
EP2254570A1 (en) 2010-12-01
MX2010008994A (es) 2010-09-07
JP5514123B2 (ja) 2014-06-04
WO2009104149A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
CY1115071T1 (el) Συνδυασμος ο οποιος περιεχει πακλιταξελη για τη θεραπευτικη αντιμετωπιση του καρκινου των ωοθηκων
CY1124617T1 (el) Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CY1118416T1 (el) Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα
CY1119942T1 (el) Μεθοδοι θεραπειας της ψωριασης χρησιμοποιωντας ανταγωνιστες της il-17
CY1121390T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
EA201171367A1 (ru) Винилиндазолильные соединения
CY1118231T1 (el) Συνθεση λιποσωματος
CY1120597T1 (el) Νεα χρηση
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CY1112595T1 (el) Αμιδοφαινοξυινδαζολια χρησιμα ως αναστολεις του c-met
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
MA32938B1 (fr) Composes organiques
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
UY34654A (es) Inhibidores de la beta-secretasa
UY34486A (es) Anticuerpos dirigidos al receptor del factor de crecimiento epidérmico 3 (her3) dirigidos contra el dominio ii del her3
UY34582A (es) Anticuerpos anti-cxcr3
CY1122025T1 (el) Βελτιωμενη διεργασια για τη δημιουργια προφαρμακων ντουοκαρμυκινης
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
CY1115251T1 (el) Θεραπεια λευχαιμιας ανθεκτικης σε ιματινιμπη χρησιμοποιωντας 4-αμινοκινολινο-3-καρβονιτριλια